RECRUITING

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

Talk to us

Conditions

Lung NeoplasmsOncogenesLung and Other Thoracic Cancers

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.

Official Title

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers

Quick Facts

Study Start:2012-01-23
Study Completion:2027-01-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01580982

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies
  2. 2. Aged 18 years or older
  3. 3. Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis.
  4. 4. Patients must have the ability to understand and willingness to sign an informed consent document.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Brandi Kubala
CONTACT
303-724-1657
brandi.kubala@cuanschutz.edu

Principal Investigator

Robert C. Doebele, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Colorado, Denver

Study Locations (Sites)

University of Colorado Cancer Center
Aurora, Colorado, 80045
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Robert C. Doebele, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2012-01-23
Study Completion Date2027-01-30

Study Record Updates

Study Start Date2012-01-23
Study Completion Date2027-01-30

Terms related to this study

Keywords Provided by Researchers

  • Oncogenes
  • Lung and Other Thoracic Cancers

Additional Relevant MeSH Terms

  • Lung Neoplasms